NouBio Inc Information

Cell and Gene Longevity Biotech has the potential to cure diseases and reverse aging in dogs and humans. However, it costs millions per dose & faces biomanufacturing limitations! NouBio Inc focuses on the creation and scaling cell-based blood and A.I. gene-edited blood therapeutics at 95% lower costs, 40% less production time and higher cell densities, to extend dog and later human lifespan. The bio-convergance of our DeepTech & A.I. platforms could turn these multi-billion dollar luxury cell-based therapies into a scalable, clinical-grade standard of care. We first used our cell-based DeepTech platform NouSerum to eliminate the unit-economic barriers that prevent scalable manufacturing of cell-based blood, therapies, vaccines, and biologics. We plan to use our A.I. gene/DNA/RNA editing tools with our additional biocomputer (POC) DeepTech platform IP to create, deliver, and scale our own custom life-saving cell and gene therapies, critical blood products for clinic/defense, and the future of age-reversal longevity treatments. We will first enable dog longevity & one day human longevity. The problem: Degenerative diseases with 0 cures are dependent on the new era of A.I. enabled cell and gene therapies to cure these diseases & reverse aging. One therapy can cost $500k- $3million+ & remains trapped at lab scale due to biomanufacturing limitations! The solution: 1. NouSerum drops cell-based production costs by 95%. Removing animal diseases from the process with no global shortages & price volatility. 2. Our A.I. tools in gene/protein/DNA/RNA editing allow us to create custom cell-based blood & therapies. Coupled with cell isolation & therapy enhancing formulas. 3. Our Bio-Microcarriers could eliminate 40% of biomanufacturing time, with no cell removal, & increased density. Connected to POCs- hollow fiber biocomputers with pulsatile flow to replace bioreactors. Mass market adoption of cell-based blood and blood therapies to extend pet and human lifespan.